| Q48111405 | Access to π-conjugated azaindole derivatives via rhodium(iii)-catalyzed cascade reaction of azaindoles and diazo compounds. |
| Q58712892 | Benzylamine and Thenylamine Derived Drugs Induce Apoptosis and Reduce Proliferation, Migration and Metastasis Formation in Melanoma Cells |
| Q64055605 | Clinical development of targeted and immune based anti-cancer therapies |
| Q36189476 | Development of a novel class of B-Raf(V600E)-selective inhibitors through virtual screening and hierarchical hit optimization |
| Q42106395 | Effects of RAF inhibitors on PI3K/AKT signalling depend on mutational status of the RAS/RAF signalling axis |
| Q36864736 | Evolving approaches to patients with advanced differentiated thyroid cancer |
| Q33632493 | Identification and synthesis of N-(thiophen-2-yl) benzamide derivatives as BRAF(V600E) inhibitors |
| Q27678754 | Identification of a Novel Family of BRAF V600E Inhibitors |
| Q39069541 | Identification of type II inhibitors targeting BRAF using privileged pharmacophores |
| Q39022580 | In silico identification of novel kinase inhibitors by targeting B-Raf(v660e) from natural products database |
| Q35434188 | Multitarget inhibitors derived from crosstalk mechanism involving VEGFR2. |
| Q38238612 | One Hippo and many masters: differential regulation of the Hippo pathway in cancer |
| Q27696222 | Optimization of diarylthiazole B-raf inhibitors: identification of a compound endowed with high oral antitumor activity, mitigated hERG inhibition, and low paradoxical effect |
| Q49021003 | Pan-Raf co-operates with PI3K-dependent signalling and critically contributes to myeloma cell survival independently of mutated RAS. |
| Q34347917 | Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors. |
| Q35847321 | The immune-related role of BRAF in melanoma |